Home
Resources
Publications
Probing and Syringing With 3% Solution of NaCl and/or 0.2 mg/ml mitomycin-C in Nasolacrimal Duct Obstruction Patients

Probing and Syringing With 3% Solution of NaCl and/or 0.2 mg/ml mitomycin-C in Nasolacrimal Duct Obstruction Patients

Raveewan Choontanom

J Med Assoc Thai. 2010 Nov;93 Suppl 6:S197-202.

PMID: 21280534

Abstract:

Objective:
To compare the efficacy of lacrimal probing and syringing among 3% solution of Sodium Chloride and/or 0.2 mg/ ml Mitomycin-C as an adjunctive medication.
Design:
A prospective, randomized, 2 by 2 factorial design study.
Material and method:
Forty-eight of nasolacrimal duct obstruction patients with epiphora symptom were randomly assigned to receive either Normal Saline Solution or 3% solution of Sodium Chloride or 0.2 mg/ml Mitomycin-C solution or combined 3% solution of Sodium Chloride with 0.2 mg/ml Mitomycin-C solution, during office probing and syringing. The intervention was performed repeatedly at week 0, weeks 2 and 4. An assessment of epiphora with Visual Analogue Scale were evaluated at week 0, weeks 2, 4, 8 and 12.
Results:
Probing and syringing was successfully reducing epiphora symptom. Mitomycin-C group showed a significant reduction in mean difference of Visual Analogue Scale score compared with Normal Saline Solution group (2.85, 95% CI: 1.164-4.536, p < 0.001) and 3% Sodium Chloride group (2.175, 95% CI: 0.489-3.861, p < 0.01). No complication or adverse event was found.
Conclusion:
0.2 mg/ml Mitomycin-C solution of was the most effective medication for office probing and syringing in reducing epiphora symptom in nasolacrimal duct obstruction patients.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP1356154921-A	17α-Hydroxyprogesterone-2,3,4-13C3 solution		1356154-92-1	Price
IAR42410500	Cortisone-2,3,4-13C3 solution			Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: